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KESAN TOKSIK, ANTI-PROLIFERATIF DAN MEKANISME KEMATIAN 
SEL OLEH LATEKS SERUM-C DAN SUB-FRAKSINYA MENGGUNAKAN 
PENGASAIAN BERPANDU SEL 
 
 
ABSTRAK 
 
Lateks daripada Hevea brasiliensis, pokok getah asli, tidak pernah dilaporkan 
sebagai ubat-ubatan tradisional walaupun kepentingan ekonominya dipandang tinggi. 
Lateks memainkan peranan biologi dalam sistem pertahanan tumbuhan terhadap 
mikroorganisma dan serangga. Oleh kerana maklumat yang terhad dalam kajian 
kesan biologi pada sistem mamalia, penilaian daya tahan sel dengan menggunakan 
MTT, penilaian PCR masa nyata (real-time PCR), penilaian kitar sel (cell cycle) dan 
penilaian profil protein telah digunakan untuk menilai kesan anti-kanser dan laluan 
kematian sel yang disebabkan oleh serum-C (WC) dan pecah-pecahannya terhadap 
warisan sel kanser asal. Pecahan serum yang selanjutnya yang digunakan dalam 
kajian ini telah disediakan melalui rawatan dialisis dan pra-haba. Ini menghasilkan 
empat pecahan daripada lateks serum-C: DCP iaitu mendakan serum-C hasil 
daripada dialisis; DCS iaitu supernatan serum-C hasil daripada dialisis; BCP iaitu 
mendakan serum-C hasil daripada pra-dipanaskan dan BCS iaitu supernatan serum-C 
hasil daripada pra-dipanaskan. Penilaian MTT mendedahkan bahawa rawatan DCS 
dan DCP adalah khusus dan menyasarkan sel-sel HepG2 dengan nilai IC50 = 0.17 
µg/mL ± 0.02 dan 1.81 µg/mL ± 0.08 masing-masing. Sel-sel MDA-MB231 didapati 
mudah terdedah kepada rawatan DCS dan DCP, dengan nilai-nilai IC50 yang terletak 
di 2.00 µg/mL ± 0.04 dan 5.49 µg/mL ± 0.01 masing-masing. DCS telah terbukti 
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lebih berkesan berbanding dengan DCP dalam kesan anti-proliferasi tertentu 
terhadap garisan sel kanser asal yang diuji. Aktiviti anti-proliferasi daripada BCP dan 
BCS yang pra-dipanaskan, dikurangkan dengan ketara dan keputusannya 
mencadangkan bahawa komponen aktif tidak dapat menahan haba. Analisa 
pengekspresian gen menggunakan PCR masa nyata, profil protein, pewarnaan sel dan 
frakmentasi DNA menunjukkan bahawa kematian sel yang disebabkan oleh DCS dan 
DCP tidak melalui kematian sel yang bergantung kepada caspase. Analisa kitaran sel 
menggunakan integrasi BrdU menunjukkan bahawa kitaran sel dirawat dengan DCS 
dan DCP terbantut dalam fasa G0/G1 kerana regulasi p21 yang tinggi (keputusan yang 
didapati daripada analisa profil protein). Tambahan pula, perubahan ultrastruktur sel 
yang dirawat dengan DCS dan DCP yang diperhatikan dengan menggunakan SEM 
dan TEM mengesahkan mekanisme kematian sel adalah dicetuskan oleh autoschizis. 
Oleh itu, selain untuk kegunaan perubatan yang berpotensi dalam rawatan kanser, 
fraksi DCS juga boleh digunakan untuk mengkaji laluan isyarat molekul yang terlibat 
dalam autoschizis. Dengan penemuan baru-baru ini, lateks Hevea brasiliensis akan 
menyumbang bukan sahaja dalam industri polimer, tetapi juga, berpotensi tinggi, 
dalam sektor farmaseutikal dan penjagaan kesihatan. 
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CYTOTOXIC EFFECT, ANTI-PROLIFERATIVE AND CELL DEATH 
MECHANISM OF LATEX C-SERUM AND SUB-FRACTIONS  
USING CELL-BASED ASSAY 
 
 
ABSTRACT 
 
Latex from Hevea brasiliensis, the natural rubber tree, has never been reported 
for folk medicinal use although highly regarded as an economic importance. Latex 
was thought to play a biological role in the plant defense system against 
microorganisms and insects. Due to scarce information available on the studies of its 
biological effects on mammalian system, cell viability assay using MTT, real-time 
PCR, cell cycle analysis and protein profiler analysis were used to evaluate the 
anticancer effects of and cell death pathway induced by whole C-serum (WC) and its 
fractions against the cancer-origin cell lines. Further fractions of the sera used in this 
study were prepared via dialysis and pre-heat treatment. The resulted four fractions 
from the whole C-serum were as follows: DCP = dialyzed C-serum precipitant; DCS 
= dialyzed C-serum supernatant; BCP = boiled C-serum precipitant and BCS = 
boiled C-serum supernatant. MTT assay revealed that DCS and DCP treatments 
specifically target HepG2 cells with IC50 values of 0.17 µg/mL ± 0.02 and 1.81 
µg/mL ± 0.08 respectively. MDA-MB231 cells were found to be susceptible to DCS 
and DCP treatments, with IC50 values at 2.00 µg/mL ± 0.04 and 5.49 µg/mL ± 0.01 
respectively. DCS was proven to be more effective compared to DCP in conferring 
specific antiproliferation effects against the tested cancer-origin cell lines. The 
antiproliferation activity of the pre-heated BCP and BCS was significantly reduced 
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and the results suggested that the active component(s) were heat-labile. Gene 
expression analysis using real-time PCR, protein profile array, cell staining and DNA 
fragmentation assay indicated that the cell death induced by DCS and DCP was not 
promoted via caspase-dependent cell death. Cell cycle analysis using BrdU 
incorporation showed that the DCS- and DCP-treated cells were arrested in G0/G1 
phase. Furthermore, ultrastructural changes of DCS- and DCP-treated cells observed 
using SEM and TEM confirmed the cell death mechanism triggered by autoschizis. 
Hence, in addition to its potential medical use in cancer treatment, DCS fraction 
could also be used to study the molecular signaling pathway(s) involved in 
autoschizis. With these recent findings, latex from Hevea brasiliensis would 
contribute not merely to the polymer industry, but also, with high potential, in the 
pharmaceutical and healthcare sectors. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Rubber in Malaysia 
The agricultural land in Malaysia is suitable for a diverse variety of tropical crops. 
Due to the availability of large agricultural land area, a number of crop plants were 
introduced by the British in the late 19th century. One of the important crops 
introduced was the rubber tree (Hevea brasiliensis) that originates from the Amazon 
basin in South America. Malaysia became an important producer when Sir Henry 
Nicholas Ridley heavily promoted the commercial production of rubber in 1881-
1911 during his tenure as the first Scientific Director of the Singapore Botanic 
Gardens.  Rubber seeds were distributed to many plantations. With concerted 
research and development, it did not take long to develop the first technique for 
tapping trees for latex without causing serious harm to the tree. Rubber tapping 
technique was considered a breakthrough as the latex can be harvested every 2-3 
days with almost the equivalent amount of latex as the very first day it was cut. 
Of all the latex-producing plants, H. brasiliensis is the only species 
successfully established as a continuous commercial supply for natural rubber. Its 
capability of producing high yield of rubber with properties suitable for the 
manufacture of rubber products proved that H. brasiliensis is a remarkable 
sustainable resource for downstream industries. Even after 20 years of tapping 
rubber, the timber of the felled rubber tree can be used to manufacture furniture and 
materials for flooring. Although the natural rubber tree may suffer from stiff 
competition from production of synthetic rubber, there is still considerable 
difference in physical and mechanical properties. Constant research is carried out in 
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order to study and improve the production of natural rubber. In Sungai Buloh 
Reserve, an experimental research station was set up during the 1930s and since then 
it has grown into an operational unit spearheading research on crop management, 
improvement and protection, besides efforts in biotechnology that includes tissue 
culture and genetic transformation of the rubber tree. 
Genetically transformed H. brasiliensis is an ideal candidate as natural 
"factories" for the production of the foreign proteins for pharmaceuticals. 
Recombinant proteins synthesised in the latex could be extracted continually and 
non-destructively by tapping the tree. Transgenic rubber trees require low 
maintenance, are environment-friendly and cost efficient as compared to bioreactor 
systems by which many pharmaceuticals are currently manufactured. Experimental 
transgenic rubber trees at the Rubber Research Institute (RRI) of Malaysia have 
successfully produced bacterial enzyme, β-glucuronidase (GUS) enzyme, mouse 
antibody and human serum albumin (retrieved from 
http://www.lgm.gov.my/RnD/biotech.aspx on 14th March 2013). 
 
1.2 Research Rationale 
 
Latex is often processed to be used in the tire, electrical and medical devices 
industry. Much research has been conducted on latex‘s phytochemical, biochemical 
and physiochemical properties in order to exploit its many industrial-related uses. 
However, there is a lack of knowledge in the bioactivities of this hydrocarbon 
polymer and with increased competition since the discovery of chemically-
synthesized isoprenes (synthetic rubber), the rubber industry is losing its luster.  
Therefore, it is upmost important to increase the latex value as a potential 
medicinal source to sustain its position in the global market. Extensive research has 
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been conducted over the years in RRI and has successfully produced stable and 
reproducible clones. Thus rubber is a more consistent counterpart when compared to 
the traditional herbs, where a full-scale research would have to be launched in terms 
of plantation, harvesting and processing, product formulation, manufacturing, safety, 
quality and standard efficacy assessment. Rubber has the advantage to be 
manufactured as a pharmaceutical therapeutic due to the years of experience at RRI. 
Not only that, the H. brasiliensis tree can be its own natural "factory" for 
pharmaceutical therapeutics production for the next 20 years.  
Research work on latex serum to explore its potential use as pharmaceutical 
therapeutics for cancer treatment began in 2006 by a group of Malaysian researchers. 
Cytotoxicity assay via spectrophotometric measurement of 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), a yellow tetrazole reduction to purple 
formazan in living cells, was adopted to determine the viability of Vero (non-cancer 
origin, African Green Monkey kidney epithelial cells) and human cervical cancer 
cells, HeLa, when treated with bark extract, latex B- and C-sera. The group managed 
to identify that the latex B- and C-sera could potentially possess active anticancer 
properties. 
Further fractionization according to the size of sera contents resulted in four 
fractions from latex B- and C-sera: BHM = B-serum high molecular weight; BLM = 
B-serum low molecular weight; CHM = C-serum high molecular weight and CLM = 
C-serum low molecular weight. In this preliminary work, BHM was found to be the 
active fraction with specific killing effects on HeLa cells while BLM, CHM and 
CLM displayed the effects with non-specificity towards the cancer cells (Ong et al., 
2009). 
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Further research work on latex B-sera, C-sera and their fractions‘ (Fig 1.3) is 
scheduled to investigate the potential of killing and the specificity of these against 
an array of human cancer cell lines. Current research work is to focus on the 
specificity and mechanism of action which the latex C-serum acts upon on specific 
human cancer cell lines. Once cytotoxicity or cell proliferation inhibition has been 
confirmed, the cell death signaling pathway will be studied to better understand the 
mechanism of action.  
Preliminary screening of Hevea latex fractions (B- and C-sera) and bark 
extract using potato tuber disc bioassay had shown that latex B-serum could inhibit 
growth of crown gall tumour (Sunderasan & Yeang, personal communication). With 
studies indicating that latex serum is potent not only to specific cancer cells but also 
against other opportunistic microbial infections (Daruliza et al., 2011), 
investigations of the latex serum as a possible therapeutic for cancer will be able to 
provide cancer patients an alternative route to combat the disease without further 
deteriorating the patient‘s health, hence allowing the body a higher chance of 
recovery.  
Latex C-serum was subjected to dialysis using SnakeSkin™ (Pierce, IL, USA) 
tubing with molecular weight cut-off 3 kDa and pre-heat treatment by immersing in 
a boiling water bath to obtain the dialyzed and pre-heated (boiled) fractions as 
specified in Figure  1.1. Research was conducted according to Figure 1.2. 
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Figure  1.1  Latex C-serum and its fractions. 
 
1.3 Research Objectives  
 To carry out cell-based cytotoxicity and anti-proliferation assay using 
whole C-serum (WC) and its further sub-fractions against an array of 
human cancer cell lines.  
 To determine the fraction that possesses the best anti-proliferation effect 
against the nine adherent human cell lines and two suspension human 
cell lines. 
 To visualize the cell death morphology of specific susceptible cell lines 
using Field Emission Scanning electron microscopy (FESEM) and 
Energy Filtered Transmission electron microscopy (EFTEM) 
 To study the downstream mechanism that trigger anti-proliferation and 
cytotoxicity effects on the cell death signaling pathway of specific 
susceptible cell lines using protein profiler analysis using RayBio® 
Human Apoptosis Antibody Array kit, gene expression analysis using 
real-time PCR and cell cycle analysis using flow cytometry with BrdU 
incorporation 
  
Latex C-serum 
Dialyzed 
Supernatant 
(DCS) 
Precipitate 
(DCP) 
Pre-heated (Boiled) 
Supernatant 
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1.4 Experimental flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.2 Flow chart of research. Refer to section 3.0 for further explanation. 
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Bax and caspase 3 genes 
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Fluorescence and transmitted light 
microscopy 
 
SEM 
 
TEM 
 
Protein profiler analysis using RayBio® 
Human Apoptosis Antibody Array kit 
 
Data Analysis 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Terpenoids 
Terpenoids constitute the most abundant and structurally diverse group of plant 
secondary metabolites that play an important role in plant-insect, plant-pathogen, 
and plant-plant interactions (Cheng et al., 2007; Zwenger & Basu, 2008). Based on 
its structures, terpenoids consist of five subclasses, including monoterpenoids, 
sesquiterpenoids, diterpenoids, triterpenoids and tetraterpenoids. Many of these 
terpenoids are identified as major bioactive constituents in traditional Chinese 
medicine (Huang et al., 2012), used for thousands of years in its clinical practices. 
Paclitaxel (Taxol®) and docetaxel (Taxotere®) are popular chemotherapeutic agents, 
derived from a class of diterpenoids called taxanes, to treat many different types of 
cancer including breast, lung, myelomas, lymphomas, and leukemias (Gligorov & 
Lotz, 2004). 
Thoppil and Bishayee conducted an extensive literature review in 2011 and 
listed terpenoid compounds such as d-limonene, cucurbitacin B, ursolic acid, β-
carotene and lycopene to have the greatest therapeutic potential for liver cancer 
prevention and treatment. Preclinical studies indicated that d-limonene not only 
inhibits tumor cell proliferation and increase acceleration of the rate of tumor cell 
death, d-limonene also induces phase I and phase II carcinogen-metabolizing 
enzymes (cytochrome p450), which metabolize carcinogens to less toxic forms and 
prevent the interaction of chemical carcinogens with DNA (Sun, 2007). Not only 
terpenoids have shown to exert biological activities but have also exhibited little or 
no toxicity to non-cancerous cells in in vitro studies. In the review, Thoppil and 
Bishayee suggested that terpenoid compounds can be used in combination with 
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other chemotherapeutic drugs and radiation therapy to enhance their therapeutic 
efficacy while limiting chemo- and radio-therapy-associated unwanted side effects. 
 
2.2 Latex from Hevea brasiliensis 
The rubber tree is primarily cultivated for the rubber particles contained in its latex, 
a milky white sticky emulsion that exudes upon damage from specialized canals 
called articulating laticiferous cells which are found on all parts of the tree – leaves, 
flowers, fruits and even the root (Kekwick, 2001; Agrawal & Konno, 2009). Latex 
from H. brasiliensis consists of many isoprene units in a long cis double bonds chain 
called polyisoprene. Latex is a terpenoid, chemically known as cis-1,4-polyisoprene 
and possesses many valuable constituents such as proteins, lipids, quebrachitol, 
ribonucleic acids and organic salts in relatively small amounts; consistent with its 
cytoplasmic nature (Chow & Draper, 1970; Bealing, 1981; Burton et al., 1985;  
Wajant & Foster, 1996; Effenberger et al., 2000). Therefore the latex from Hevea 
brasiliensis has a wide range of high molecular weight distribution. 
Latex can be separated into three fractions consisting of the rubber cream on 
the top layer, clear centrifuged serum (C-serum) in the middle portion and a thick 
pale yellowish bottom fraction after high speed centrifugation. The bottom fraction 
mainly contains vacuole-like organelle known as lutoid body.  The fluid released 
from a continuous freeze-thaw cycle to rupture the lutoid bodies is known as B-
serum (Figure  2.1). Lutoid particles have long interested biochemists because they 
resemble lysosomes in the cells and are considered the site with the most hydrolytic 
activity and pathogenesis-related proteins (Wititsuwannakul & Wititsuwannakul, 
2001).  
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Figure ‎2.1  The separated zones of Hevea brasiliensis natural latex can be 
observed after centrifugation. The various zones are distinguishable by colour or 
texture or both. (White rubber layer, clear solution and yellowish pellet). Clear 
solution is the latex C-serum solution. 
 
2.2.1 Latex B-serum 
B-serum is the fluid released from ruptured lutoid bodies with seven anionic proteins 
and six cationic proteins (Subramaniam, 1995). Lutoid bodies are osmotically active 
spheres of a single layer membrane measured about 1-3 µm in diameter 
(Wititsuwannakul & Wititsuwannakul, 2001). The lipids of lutoid membrane are 
rich in phosphotidic acids and saturated fatty acyl residues that play an important 
role in colloidal stability in latex (Dupont et al., 1976). The fluid inside these lutoid 
bodies contains high acid hydrolase content similar to lysosomes and is rich with 
microfibrils that act as nitrogen reserves. B-serum contains approximately 50% of 
Hevein, a chitin-binding protein and 30% of Hevamine, a plant defense protein 
(Wititsuwannakul & Wititsuwannakul, 2001). Although not much is known about 
 
Rubber 
Cream 
Frey-
Wyssling 
particles 
C-serum 
B-serum 
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the enzymes and proteins found in B-serum, it is thought that the contents of the 
lutoid bodies play a role in the metabolic processses and homeostasis in latex, as 
well as metabolic interactions with latex C-serum. Chitinase and β-1,3-gluconase 
found in B-serum are also implicated  in wound response induced by the multiple 
tappings that serve as a protection against possible attacks from pathogenic 
microorganism (Wititsuwannakul & Wititsuwannakul, 2001).  
 
2.2.2 Latex C-serum 
Latex C-serum is the metabolically active fraction where all the glycolytic enzymes 
and cytosolic enzymes for isoprenoid pathway are found in the laticiferous 
cytoplasm. Rich with organic compounds, about 200 polypeptides (60% of the latex 
protein) can be found in the C-serum. Comprised of nineteen anionic proteins and 
five cationic proteins, its major component is α-globulin (pI =4.55) that has been 
reported to act as protein storage in the seeds of plants. However α-globulin was 
thought to play an important role in latex and rubber particles‘ colloidal stability due 
to its high binding affinity for adsorption into rubber particles (Archer et al., 1963). 
C-serum also contains a heat-stable calcium-binding protein called Calmodulin 
which activates HMG-CoA reductase in the lutoids found in B-serum 
(Wititsuwannakul et al., 1990). Wititsuwannakul et al. (2008) recently identified 
another protein in the C-serum that plays an anti-coagulating role in maintaining 
colloidal stability in the latex called Hevea latex lectin-binding protein (HLL).  
Other than sucrose, glucose, fructose and raffinose, quebrachitol or chemically 
known as 1-methyl inositol makes up about 75% to 95% of the total carbohydrates 
present in the C-serum (Bealing, 1981). Major amino acids found in C-serum are 
alanine, aspartic acid, glutamic acid and its amide. Malic and citric acid makes up 
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for 90% of its organic acids, while glutathione, cysteine and ascorbic acid are the 
reducing agents found in C-serum (d‘Auzac and Jacob, 1989; Wititsuwannakul and 
Wititsuwannakul, 2001). However, the primary metabolic and physiological 
functions of these components are still poorly understood.  
 
2.2.3 Latex allergens 
Latex allergy was first reported in 1979, even though irritant and delayed-contact 
reactions to rubber products were increasingly recognized since 1927 (Ownby 2002). 
Both Latex B- and C-sera are known to contain proteins, and a multitude of organic 
compounds as shown in Table 2.1 (Archer et al., 1969). According to Archer et al. 
(1969) and Subramaniam (1995), latex B-serum mainly consists of a protein rich in 
sulfur called Hevein (50%), a chitin-binding protein and Hevamine (30%), a plant 
defense protein, which has also been identified as major allergens to humans.  
According to Yeang et al. (2002), latex C-serum contains four of the 
fourteen International Union of Immunological Societies (IUIS)-recognized latex 
allergens, which are Hev b 5, 7, 8, and 9. The most important allergen of this 
subgroup is Hev b 5, a heat-stable protein (Rihs and Raulf-Heimsoth, 2003; 
Beezhold et al., 2004). However, all of the recognized allergenic proteins located in 
the latex bottom fraction—Hev b 2, 4, 6, and 10. The molecular weight of identified 
latex allergens are as in Table 2.2. 
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Table ‎2.1 Composition of fresh natural latex (reproduced from Subramaniam, 
1995. The chemistry of natural rubber latex. Immunology and Allergy Clinics of 
North America 15, p. 2, Table 1.) 
Component Content * (%, weight/ volume) 
Rubber hydrocarbon 25-45 
Protein 1.0-1.8 
Carbohydrate 1.0-2.0 
Neutral lipids 0.4-1.1 
Polar lipids 0.5-0.6 
Inorganic constituents 0.4-0.6 
Amino acids, amines etc. 0.4 
water - 
*The percentage content of the components varies according to clonal variations of 
the rubber clones 
 
Table ‎2.2  Natural rubber latex allergens recognized by the International Union 
of Immunological Societies (IUIS) (reproduced from Yeang et. al., 2002 Allergenic 
proteins of natural rubber latex. Methods 27, p.34, Table 2 with updates) 
IUIS code Identity 
Molecular mass 
(kDa) 
Location in latex 
Hev b 1 
Rubber elongation factor 
(REF) 
{14.6}
28
, 58
b
 Rubber particles 
Hev b 2 β-1,3-Glucanase 
[36]
d
, 36
76
, 34–
36
75;79, 
(35)
44
 
B-serum 
Hev b 3 
Small rubber particle 
protein (SRPP) 
[22–23]27, (22)25;43 Rubber particles 
Hev b 4 
Microhelix, 
cyanogenicglucosidase 
50–57e B-serum 
Hev b 5 Acidic protein [16]
47 
(16.0)
47
 C-serum 
Hev b 6.01 
Hev b 6.02 
Hev b 6.03 
Prohevein 
Hevein 
Prohevein C terminus 
20
90 
(19c)
24
 
{4.7}
84
 (4.7)
24 
14
90
 (13.3c)
24
 
B-serum 
Hev b 7.01 
 
Hev b 7.02 
patatin homologue from 
B-serum 
patatin homologue from 
C-serum 
42.9 
 
[44]
56
 (43)
57;58
 
B-serum 
 
C-serum 
Hev b 8 Prolin 
10.2, 14.2, 15.7
64 
(14.0)
66
 
C-serum 
Hev b 9 Enolase 51
36
, 48
71
 (48)
71
 C-serum 
Hev b 10 Mn-superoxidedismutase 45
101
, 25
36
 (23)
102;103
 B-serum 
Hev b 11 class I endochitinase 33 B-serum 
Hev b 12 lipid transfer protein 9 B-serum 
Hev b 13 
(= Hev b 
7.01) 
latex esterase 
Early nodule specific 
protein (ENSP) 
42.9 B-serum 
Hev b 14 Hevamine 30 B-serum 
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2.2.4 Latex as a medicinal source for cancer 
Due to its allergenic nature, latex has never been thought to possess any medicinal 
properties even though latex had strongly been implicated in plant‘s defense against 
herbivorous insects (Agrawal and Konno, 2009) and microorganisms (Van Parijs et 
al., 1991). Latex B- and C-sera possess plant defense proteins but identified as 
allergenic proteins to humans (Yeang et al., 2002). Latex was thought to have a 
primary role in entrapping whole insects in its sticky emulsion (Agrawal and Konno, 
2009). The elasticity of its cis-polyisoprene structure, coagulation of its rubber 
particles and the adhesiveness of rubber particles to the surfaces of the insects play 
important roles in this clever entrapment. 
Latex from H. brasiliensis has also been reported to possess specific 
antimicrobial properties (Daruliza et al., 2011). Hevein was found to possess strong 
antifungal properties against human pathogenic fungi including Candida albicans, 
Candida tropicalis, Candida krusei and Candida glabrata. Hevein is a small protein 
with a molecular size of 4.7 kDa that could penetrate and bind to the pathogenic 
fungal cell wall matrix and caused a Ca
2+
-dependent aggregation in fungal cell wall 
(Kanokwiroon et al., 2008). This could prove a valuable finding as synthetic 
antifungal drugs available for the treatment of Candida infections have very serious 
side effects to immunocompromised and AIDS patients who suffer from immune 
dysfunction. For instance, Fluconazole and Itraconazole, two very popular 
antifungal drugs, have significant negative interactions with chemotherapeutic drugs 
and AIDS-related drugs (Albengras et al, 1998). Besides that, multidrug resistance 
has emerged in recent years due to the widespread use of antibiotics and 
immunosuppressive agents (Vandeputte et al., 2012). However, further work may 
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need to be conducted in order to remove or mask the allergenicity without losing its 
antifungal property. 
 
2.3 Cancer in Malaysia 
Cancer remains a rapid growing problem that seeks a global attention. In Malaysia 
alone, the overall age-standardized incidence (ASR) for males was 85.1 per 100,000 
population and 94.4 per 100,000 population for females (Malaysia National Cancer 
Registry Report 2007 by Malaysia Ministry of Health, 2011) with breast cancer 
being in the lead rank followed by colorectal cancer. Oncologists have predicted 
from the increased number of cases (year-to-year) that cancer would surpass 
cardiovascular disease taking its leading rank as the main cause of death as early as 
2030 with more than 13.2 million deaths (Boyle and Levin, 2010). Thus, researchers 
are relentlessly learning about cancer in order to discover any forms of potential 
remedy or useful natural substances that may fight against cancer specifically. It is 
thought that these would cause less side-effects compared to those synthetic drugs 
that chemically induce cell death in cancer cells (Hamblin, 2006). 
 
2.3.1 Cancer progression 
Cancer is a disease where cell proliferation occurs without any cell regulation and 
continues to divide abnormally (Cancer Facts & Figures 2016 by American Cancer 
Society, 2016). These cancer cells have the potential to break free from its original 
cells and travel in the blood or lymphatic system in order to invade and spread to 
other parts of the human body. These type of cancer cells are considered malignant 
with invasive characteristics, whereas cancer cells which grow into a solid tumor 
mass without any invasive characteristics are known as benign tumors, which can be 
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surgically excised. Cancer cells do not mature into distinct cell types with specific 
functions, unlike normal cells (National Cancer Institute, 2016). This is one of the 
reasons cancer cells continue to grow uncontrollably.  
 
2.3.1(a) Cell cycle regulation 
This uncontrolled growth is influenced by genetic factors such as DNA mutation, 
hereditary oncogenes and ―faulty‖ tumor suppressor genes that affect the normal cell 
cycle. The cell cycle governs the cell replication and division process of the cell into 
two daughter cells. The cell cycle is divided into four sequential phases, namely G1 
phase, S phase where DNA replication occurs, G2 phase and mitosis also known as 
M phase where the cell divides into two daughter cells. The sequential phases follow 
a strict regimen and this regimen does not allow mitosis to occur unless DNA 
synthesis has completed and vice versa (Garrett, 2001). The cell cycle has strict 
checkpoints at each G1 and G2 phases in order to check and ensure DNA replication 
and mitosis has been conducted before the cell continues to the next phase of the cell 
cycle (Figure  2.2).  
The first checkpoint occurs at the G1/S phase transition and is a major sensor 
of DNA damage. Cells may be arrested in S phase due to incomplete DNA 
replication or any DNA damage. Next checkpoint occurs at G2/M checkpoint, which 
monitors the fidelity of DNA replication and like the G1/S checkpoint is an 
important sensor of DNA damage. Another checkpoint occurs at the mitosis phase 
known as the spindle checkpoint where if a functional mitotic spindle has not been 
formed correctly, cell cycle arrest occurs (Garrett, 2001). For cells that did not 
receive enough cues and signals for proliferation will not be able to go through the 
restriction point (R) and remain in G0 phase. These cues and signals depend on 
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cyclin dependent kinase (Cdk) family that governs the cell cycle progression 
through specific protein phosphorylation at each phase (Garrett, 2001; Malumbres 
and Barbacid, 2007). 
 
Figure ‎2.2  Schematic representation of the cell cycle and its checkpoints. 
(Figure reproduced from Garrett, 2001. Cell cycle control and cancer. Current 
Science 81:5 p.515, Figure 1). 
 
2.3.1(b) Environmental factors 
Environmental factors such as lifestyle, stress, diet, and even exposure to cancer-
causing substances, chronic inflammation and infectious agents plays a role in 
cancer progression (Cancer Facts & Figures 2016 by American Cancer Society, 
2016). One example of infectious agent is Helicobactor pylori, a spiral-shaped, 
Gram-negative bacterium, that grow in the digestive tract and have a tendency to 
attack the stomach lining that cause ulcers in the stomach and small intestine 
(Wroblewski et al., 2010). Infection with H. pylori is the strongest known risk factor 
for gastric cancer and was declared as type I carcinogen in 1994 (Parkin et al., 2005). 
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 In 2010, the Malaysian Ministry of Health (MOH) started human 
papillomavirus (HPV) vaccination programme for preteen girls aged 13 (MaHTAS 
by MOH Malaysia, 2011). HPV infections are a common, sexually transmitted 
disease with more than 130 subtypes and about 70 subtypes infect human (Kawana 
et al., 2009). High-risk HPV genotypes have been associated to cervical cancer 
(Burd, 2003). Although many developing and developed countries have initiated this 
vaccination programme, it is still highly recommended for women 30 years above to 
conduct regular screenings (Burd, 2003; WHO Factsheet 2016). This is because the 
two HPV vaccines developed and approved, Gardasil®, a quadrivalent vaccine 
which targets HPV-6, -11, -16 and -18 and Cervarix®, a bivalent vaccine which 
targets HPV-16 and -18, contains only L1 virus-like particles (VLPs) derived from 
HPV-16 and -18 which are most frequently associated with cervical cancer but not 
the other possible subtypes associated with cervical cancer (Kawana et al. 2009). 
 
2.3.2 Cancer description and stage 
Clinicians and doctors determine the severity of cancer through a method called 
staging. Staging describes the extent or spread of cancer at the time of diagnosis. 
Proper staging is essential for the doctors and clinicians to assess the prognosis and 
to optimize therapy options available (Cancer Facts & Figures 2016 by American 
Cancer Society, 2016). Generally, a cancer stage is based on the size or extent of the 
primary tumor (T), whether it has spread to nearby lymph nodes, therefore absence 
or presence of regional lymph node involvement (N) or it has spread to other areas 
of the body, the absence or presence of distant metastases (M). Once the T, N, and 
M categories are determined, a stage of 0, I, II, III, or IV is assigned, with stage 0 
being in situ, stage I being early, and stage IV being the most advanced disease 
18 
 
(Cancer Facts & Figures 2016 by American Cancer Society, 2016). Different cancer 
types require different staging methods that involve descriptive and statistical 
analysis, such as leukemia, brain and spinal cord tumors (National Cancer Institute, 
2016).  
 
2.3.3 Cancer treatment 
Cancer treatments available in Malaysia are quite extensive, ranging from surgery to 
chemotherapy comprising of one or more chemotherapeutic drugs, to modernized 
radiotherapy referred as stereotactic radiosurgery (SRS) and stereotactic radiation 
therapy (SRT). SRT uses high energy x-ray beam to shrink or control the growth of 
a tumor or abnormal cells by either killing the cells directly or by disrupting the 
ability of the cells to grow. Both the SRS and SRT are similar but different in 
dosage quantities during radiation. SRS delivers a large dose of radiation at a single 
time, whereas SRT delivers lower dose of radiation over a period of fractionated 
treatment schedule (Halasz and Rockhill, 2013). 
Chemotherapeutic drugs or agents consist of a variety of molecules that act 
upon actively proliferating cells, without differentiating cancer cells from normal 
cells. Therefore normal cells are destroyed as well and this causes unwanted side-
effects to the patients.  One example is alkylating agents such as mechlorethamine 
(nitrogen mustard) that directly form covalent bonds at two nucleophilic sites on 
different DNA bases to induce interstrand (between two opposite strands) and/or 
intrastrand (on same strand) cross-links to keep the cell from proliferating (Siddik, 
2002). Alkylating agents act on all phases of the cell cycle and are used to treat 
many different cancers, including leukemia, lymphoma, Hodgkin disease, multiple 
myeloma, and sarcoma, as well as cancers of the lung, breast, and ovary. 
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Antimetabolite drugs were among the first effective chemotherapeutic agents 
discovered and are folic acid, pyrimidine or purine analogues that interfere with 
DNA and RNA replication by competing and substituting essential pyrimidine or 
purine required for normal physiological functions. Generally, antimetabolites such 
as 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), Fludarabine and Methotrexate 
induce cell death during the S phase of cell growth when incorporated into RNA and 
DNA or inhibit enzymes needed for nucleic acid production, causing DNA damage 
and apoptosis induction (Sampath et al., 2003; Parker, 2009). 
Doxorubicin is commonly used to treat leukemia, Hodgkin's lymphoma and a 
wide variety of cancers. Doxorubicin is an anthracycline, an anti-tumor antibiotics 
that interfere with enzymes involved in DNA replication in the cell cycle. It also 
causes buildup of free oxygen radicals that induce DNA and cell membrane damage 
(Sangeeta, 2014). However, anthracyclines can permanently damage the heart and 
weaken the heart muscles if given long term (Cardinale et al., 2010).  
Topoisomerase inhibitors are another group of chemotherapeutic drugs, which 
act upon the topoisomerase enzyme responsible for the uncoiling and coiling of the 
double helix strands during DNA replication in the S phase. Topoisomerase 
inhibitors will bind to the topoisomerase molecule, rendering it nonfunctional and 
unable to bind DNA back together after it has been cut. Therefore cuts are made to 
either one or both strands of the DNA molecule which are never repaired, ultimately 
leading to death of the cell (Ewesuedo and Ratain, 1997; Binashi et al., 1995). 
Chemotherapeutic drugs also consist of mitotic inhibitors, which are often 
plant alkaloids and other compounds derived from natural products (Zulkipli et al., 
2015). Mitotic inhibitors function by inhibiting cell division or mitosis in the M 
phase, where a single cell divides into two genetically identical daughter cells. 
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Mitotic inhibitors bind to tubulin and inhibit its polymerization into microtubules 
(Sudakin and Yen, 2007). Taxanes such as paclitaxel (Taxol®) and docetaxel 
(Taxotere®) and vinca alkaloids such as vinblastine (Velban®), vincristine 
(Oncovin®), and vinorelbine (Navelbine®) are some of the examples of mitotic 
inhibitors (Zulkipli et al., 2015). Nerve damage may occur if administrated in high 
doses (Bass and Ahmad, 2013). 
Other forms of chemotherapeutic drugs require more targeted therapies in 
order to reduce the side effects cancer patients suffer from chemotherapy. Such 
example is Imatinib, a tyrosine-kinase inhibitor that kills cancer cells by blocking 
the action of tyrosine kinases. Imatinib is particularly useful in Philadelphia 
chromosome-positive (Ph+) chronic myelogenous leukemia (CML) cells where one 
tyrosine kinase enzyme, BCR-Abl, is constantly actively adding phosphate groups. 
Fortunately, this BCR-Abl tyrosine kinase enzyme exists only in cancer cells and 
not in healthy cells, thus Imatinib works as a form of targeted therapy, where only 
cancer cells are killed through the drug's mechanism (Goldman & Melo, 2003). 
Rituximab (Mabthera®) is another form of targeted therapy which uses 
monoclonal antibodies also known as immunotherapy that targets specific protein 
receptors on the surface of cells. Rituximab is used to treat non-Hodgkin lymphoma 
(NHL) and chronic lymphocytic leukaemia (CLL), as it specifically targets CD20 
antigens on B lymphocytes. Even though CD20 antigens are available on the surface 
of normal B-cells and Rituximab will sensitize both malignant and normal B-cells to 
be killed, full recovery of normal B-cells in the peripheral blood is usually seen 9-12 
months after therapy (Plosker and Figgitt, 2003).  
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2.4 Programmed cell death (PCD) – Apoptosis  
Programmed cell death (PCD) has long been studied in the structural and 
developmental systems biology. It is an important biological process that regulates 
and eliminates unwanted cells such as those with potentially harmful genomic 
mutations, autoimmune reactive lymphocytes and virally-infected cells (Fesik, 2000). 
Kerr et al. first coined the word ―apoptosis‖ in 1972 after observing a well-
organized and conserved mechanism with unique morphological features that often 
occurs during cell death. During apoptosis, the cell receives a ―death‖ signal and 
begins to shrink and loses its viability with chromatin condensation, plasma 
membrane blebbing and nuclear DNA fragmentation within its cellular compartment 
(Wyllie 1980). The apoptotic bodies are then engulfed by macrophages and thus are 
removed from the tissue without causing an inflammatory response.  
This highly controlled sequence of events is very important in embryogenesis, 
development of reproductive system, homeostasis of the immune system and only 
occurs in the cells which have been internally predetermined to die (Gewies, 2003). 
This programmed cell death is so precisely executed that in the development of the 
nematode Caenorhabditis elegans, exactly 131 cells die according to a well-
regulated genetic programme (Hengartner and Horvitz, 1994). Apoptosis plays a 
protective mechanism, directing lysis of virus-infected cells, foreign cells or 
incipient neoplasm. Over-regulated PCD can contribute to the acquired immune 
deﬁciency syndrome (AIDS) and neurodegenerative diseases like Alzheimer and 
Parkinson syndromes, and ischaemic injury such as myocardial infarction. Under-
regulated PCD could lead to cancer, persistent viral infection, or autoimmune 
disorders. In short, apoptosis is an active, metabolic, genetically encoded and 
evolutionarily selected death pathway. 
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Apoptosis can be triggered by various stimuli from outside or inside the cell, 
dividing its signaling pathway to extrinsic and intrinsic pathways. The extrinsic 
pathway begins outside a cell, when conditions in the extracellular environment 
determine that a cell must die. Based on the triggering stimulus and nature of the 
components involved, at least two apoptotic pathways can be differentiated; one 
involving receptor systems and the other triggered by cytotoxic stress. Apoptosis has 
been widely studied by scientists in order to determine whether cell death 
occurrence by an active molecule is triggered by receptor systems or cytotoxic stress 
to improve drug deliverance to its actual active site and reduce the risks for drug 
suppression. 
 
2.4.1 Extrinsic pathway 
The extrinsic pathway involves the activation of ―death receptors‖ which are cell 
surface receptors that transmit apoptotic signals upon binding with specific ligands 
such as tumour necrosis factor receptor (TNFR) gene superfamily. The TNFR 
family is a large family consisting of 29 transmembrane receptor proteins, organized 
in homotrimers and activated through binding of respective ligand(s) (Figure  2.3). 
There are at least 19 members of the TNF ligand family and each binding may result 
in a number of different responses including proliferation, inflammation and 
apoptosis, depending on the adaptor proteins associated with the activated receptor 
(Aggarwal, 2003). For example, TNFR may also stimulate pro inflammatory 
pathways leading to activation of NFκB (Nuclear factor kappa-light-chain-enhancer 
of activated B cells), through the binding of receptor interacting protein, RIP to 
TNFR type 1-associated death domain protein (TRADD). Popular death receptors 
that mediate apoptosis are the tumour necrosis factor receptor (TNFR-1), Fas/CD95, 
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and the tumour necrosis related apoptosis-inducing ligand (TRAIL) receptors DR-4 
and DR-5, which binds to TNFα, CD95 and TRAIL, respectively (Figure  2.3).  
 
Figure  2.3  Schematic representation of the extrinsic apoptosis pathway. The 
extrinsic apoptosis pathway is activated upon ligand binding to death receptors 
(TNFR1, Fas/CD95, DR4/5) which results activation of a caspase cascade and 
eventually cleavage of both cytoplasmic and nuclear substrates. The extrinsic 
apoptosis pathway indirectly triggers and often converges with the intrinsic pathway 
in the caspase cascade causing cellular shrinkage, membrane blebbing and DNA 
fragmentation, hallmarks of apoptosis cell death (Figure reproduced from Krakstad 
and Chekenya, 2010. Survival signalling and apoptosis resistance in glioblastomas: 
opportunities for targeted therapeutics. Molecular Cancer, 9:135 p.7 of 14, Figure 3). 
 
Subsequent signaling is mediated by the cytoplasmic part of the death receptor, 
which contains a conserved sequence termed the death domain (DD) and forms a 
death inducing signaling complex (DISC) to activate the initiator caspase-8 and 
caspase-10. Activated caspase-8 or caspase-10 then initiates a caspase cascade by 
processing the effector caspases-3, -6, and -7 which in turn cleave a number of 
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protein substrates. Cleavage of caspase substrates eventually leads to the 
characteristic morphological and biochemical features of apoptosis (Gewies, 2003; 
Elmore, 2007). The activated caspase-8 also triggers BH3 interacting-domain death 
agonist, known as BID in activating pro-apoptotic BAX protein (BCL-2-associated 
X protein) and/or BAK protein (BCL-2-antagonist/killer-1) to form an oligomeric 
pore known as mitochondrial apoptosis-induced channel (MAC) that governs the 
release of cytochrome c. This is where the extrinsic and intrinsic apoptosis pathway 
meets and converges as one leading up to a series of events in apoptosis cell death. 
Kruger et al. (2001) summarized that the activation of caspase-8 could be prevented 
by FLICE inhibitory protein (FLIP) as a potential competitive inhibitor. 
 
2.4.2 Intrinsic pathway 
The intrinsic pathway involves the mitochondria as a central role in the integration 
and propagation of death signals originating from inside the cell such as DNA 
damage, oxidative stress, starvation, hypoxia as well as those induced by 
chemotherapeutic drugs. These stress-inducing signals then disrupt the 
mitochondrial inner transmembrane potential (∆ψ) and cause the sudden increase of 
the inner mitochondrial membrane permeability to solutes with a molecular mass 
below approximately 1.5 kDa. Due to this, osmotic swelling occurs in the 
mitochondria and ruptures the outer mitochondrial membrane, resulting in the 
release of pro-apoptotic proteins from the mitochondrial intermembrane space into 
the cytoplasm. Released proteins include cytochrome c and dATP binds to the Apaf-
1 protein and forms the apoptosome, a cytosolic death signalling protein complex 
that triggers the activation of procaspase-9 (Gewies, 2003; MacFarlane and 
Williams, 2004; Elmore, 2007; Taylor et al., 2008).  The activated caspase-9 
